美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

OneStream, Inc.

18.89

+0.77004.25%

盘后：18.86-0.0292-0.15%18:59 EDT

成交量：135.48万

成交额：2,535.90万

市值：45.87亿

市盈率：-10.08

高：19.11

开：18.13

低：17.78

收：18.12

52周最高：35.39

52周最低：16.51

股本：2.43亿

流通股本：2.18亿

量比：0.66

换手率：0.62%

股息：- -

股息率：- -

每股收益(TTM):-1.8746

每股收益(LYR):-1.2330

净资产收益率：-109.08%

总资产收益率：-36.30%

市净率：10.01

市盈率(LYR):-15.32

数据加载中...

总览公司新闻公告

CounterPoint：AI手机不到2年全球累计出货量破5亿台

Onestream, Inc.盘中异动临近收盘快速拉升5.02%

Os Therapies Incorporated盘中异动股价大涨6.08%

三大运营商eSIM商用启幕哪些产业链企业受益？|eSIM重返系列观察①

每日经济新闻

Os Therapies Incorporated盘中异动快速下跌5.14%报1.76美元

告别繁琐！让AI当你的“生活管家”，是种怎样的体验？

科伦博泰旗下抗癌药新适应症获批，上半年该药贡献超9成药品销售收入

红星资本局

防晒剂龙头创始人逝世

德达博妥单抗三阴乳腺癌一线治疗新突破

第一三共公布TROPION-Breast02 Ⅲ期研究积极的主要结果

破局肺癌长生存难题百泽安全线刷新OS获益纪录

Os Therapies Incorporated盘中异动早盘急速跳水6.67%报2.05美元

医保基金监管细则公开征求意见发布；第一三共新生产大楼开工

21世纪经济报道

打败“药王”后康方出海数据屡发股价屡跌

泰瑞沙联合化疗方案显示出近四年的中位总生存期（OS），这是EGFR敏感突变阳性晚期非小细胞肺癌全球III期临床研究中报道的最长*生存获益

百济神州今日宣布RATIONALE-315研究的最终分析结果和RATIONALE-303研究的长期随访数据显示百泽安（替

中信里昂：维持康方生物(09926.HK)目标价177港元评级“跑赢大市“

1400亿广东明星药企，筹资35亿出征全球

21世纪经济报道

“大牛股”康方生物，核心产品大卖亏损却扩大

时代财经APP

康方生物Key data readouts for AK112 to validate

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OS/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","market":"US","secType":"STK","nameCN":"OneStream, Inc.","latestPrice":18.89,"timestamp":1761940800000,"preClose":18.12,"halted":0,"volume":1354769,"hourTrading":{"tag":"盘后","latestPrice":18.8608,"preClose":18.89,"latestTime":"18:59 EDT","volume":31206,"amount":589472.326,"timestamp":1761951555580},"delay":0,"floatShares":218155803,"shares":242844600,"eps":-1.874642,"marketStatus":"休市中","change":0.77,"latestTime":"10-31 16:00:00 EDT","open":18.125,"high":19.11,"low":17.775,"amount":25359049.794533003,"amplitude":0.073675,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.874642,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1762160400000},"marketStatusCode":7,"adr":0,"listingDate":1721793600000,"exchange":"NASDAQ","adjPreClose":18.12,"preHourTrading":{"tag":"盘前","latestPrice":18.42,"preClose":18.12,"latestTime":"09:01 EDT","volume":779,"amount":14369.570325,"timestamp":1761915683866},"postHourTrading":{"tag":"盘后","latestPrice":18.8608,"preClose":18.89,"latestTime":"18:59 EDT","volume":31206,"amount":589472.326,"timestamp":1761951555580},"volumeRatio":0.656793,"impliedVol":0.8184,"impliedVolPercentile":0.908},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OS\",,,,,undefined,":{"symbol":"OS","floatShares":218155803,"roa":"-36.30%","roe":"-109.08%","lyrEps":-1.232998,"volumeRatio":0.656793,"shares":242844600,"dividePrice":0,"high":19.11,"amplitude":0.073675,"preClose":18.12,"low":17.775,"week52Low":16.51,"pbRate":"10.01","psRate":"8.41","week52High":35.39,"institutionHeld":0,"latestPrice":18.89,"eps":-1.874642,"divideRate":0,"volume":1354769,"delay":0,"ttmEps":-1.874642,"open":18.125,"prevYearClose":28.52,"prevWeekClose":17.99,"prevMonthClose":18.43,"prevQuarterClose":18.43,"fiveDayClose":17.99,"twentyDayClose":18.51,"sixtyDayClose":22.22,"earningDate":1762358400000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OS\",params:#limit:5,,,undefined,":[{"date":"2025-11-06","symbol":"OS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"defaultRemindTime":1762462800000,"name":null,"time":"盘后","dateTimestamp":1762405200000,"actualEps":null},{"market":"US","date":"2025-08-07","symbol":"OS","fiscalQuarterEnding":"2025/06","expectedEps":0.01,"name":null,"time":"盘后","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-05-08","symbol":"OS","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"盘后","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-02-11","symbol":"OS","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"盘后","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2024-11-07","symbol":"OS","fiscalQuarterEnding":"2024/09","expectedEps":0,"name":null,"time":"盘后","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.06}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5714,"hold":0.0952,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":21,"updateTime":1753329600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OS","date":"2025-10-30","current":-10.076591,"percent":0.961415,"low":-1655.61542,"twenty":-395.977809,"median":-20.993156,"eighty":-15.87621,"high":-12.620803,"avg":-258.85588,"sd":513.732645,"marketCap":3385947466},"quantilePoints":[{"date":"2024-08-02","current":-402.058638,"twenty":-402.058638,"median":-402.058638,"eighty":-402.058638,"marketCap":4348264172},{"date":"2024-08-09","current":-394.529993,"twenty":-398.004752,"median":-394.602383,"eighty":-391.489578,"marketCap":4266841869},{"date":"2024-08-16","current":-420.156344,"twenty":-402.058638,"median":-395.977809,"eighty":-394.529993,"marketCap":4543990864},{"date":"2024-08-23","current":-418.563746,"twenty":-420.156344,"median":-400.248867,"eighty":-394.674774,"marketCap":4526766915},{"date":"2024-08-30","current":-439.701867,"twenty":-427.829772,"median":-415.668113,"eighty":-395.977809,"marketCap":4755375690},{"date":"2024-09-06","current":-1412.285699,"twenty":-434.093948,"median":-420.156344,"eighty":-395.977809,"marketCap":4652069092},{"date":"2024-09-13","current":-1421.532228,"twenty":-630.517125,"median":-426.381956,"eighty":-397.599363,"marketCap":4682527160},{"date":"2024-09-20","current":-1491.611188,"twenty":-1406.835113,"median":-428.55368,"eighty":-398.352228,"marketCap":4913367253},{"date":"2024-09-27","current":-1641.015636,"twenty":-1479.542034,"median":-435.672004,"eighty":-401.33473,"marketCap":5405505506},{"date":"2024-10-04","current":-1582.129844,"twenty":-1582.616503,"median":-445.348351,"eighty":-408.313205,"marketCap":5211535706},{"date":"2024-10-11","current":-1384.546111,"twenty":-1557.991535,"median":-1361.673117,"eighty":-414.50986,"marketCap":4560694889},{"date":"2024-10-18","current":-1422.505547,"twenty":-1506.405635,"median":-1387.466067,"eighty":-417.984619,"marketCap":4685733272},{"date":"2024-10-25","current":-1513.510863,"twenty":-1501.052381,"median":-1410.582391,"eighty":-419.837824,"marketCap":4985504782},{"date":"2024-10-31","current":-1488.204572,"twenty":-1545.825049,"median":-1419.58559,"eighty":-422.588676,"marketCap":4902145859},{"date":"2024-11-08","current":-29.444986,"twenty":-1544.267739,"median":-1421.532228,"eighty":-422.588676,"marketCap":5359016876},{"date":"2024-11-15","current":-29.547337,"twenty":-1525.190689,"median":-1414.232336,"eighty":-406.749563,"marketCap":5377644907},{"date":"2024-11-22","current":-27.361909,"twenty":-1504.167001,"median":-1405.472467,"eighty":-395.977809,"marketCap":4979894851},{"date":"2024-11-29","current":-26.339693,"twenty":-1496.769778,"median":-1384.546111,"eighty":-392.705744,"marketCap":4793850470},{"date":"2024-12-06","current":-28.33551,"twenty":-1493.655158,"median":-903.058146,"eighty":-29.829328,"marketCap":5157091209},{"date":"2024-12-13","current":-28.454992,"twenty":-1490.248542,"median":-439.701867,"eighty":-28.749622,"marketCap":5178836972},{"date":"2024-12-20","current":-27.223413,"twenty":-1484.895288,"median":-431.521704,"eighty":-28.258307,"marketCap":4954688343},{"date":"2024-12-27","current":-27.048786,"twenty":-1479.834029,"median":-428.191726,"eighty":-28.004145,"marketCap":4922906075},{"date":"2025-01-03","current":-25.973452,"twenty":-1479.444702,"median":-426.381956,"eighty":-27.732022,"marketCap":4727194212},{"date":"2025-01-10","current":-24.227183,"twenty":-1479.444702,"median":-422.183287,"eighty":-27.252823,"marketCap":4409371530},{"date":"2025-01-17","current":-26.460569,"twenty":-1468.54353,"median":-415.668113,"eighty":-26.869269,"marketCap":4815850013},{"date":"2025-01-24","current":-27.894348,"twenty":-1465.818237,"median":-402.058638,"eighty":-26.861301,"marketCap":5076799163},{"date":"2025-01-31","current":-27.407231,"twenty":-1462.314289,"median":-396.991281,"eighty":-26.925021,"marketCap":4988143362},{"date":"2025-02-07","current":-27.09474,"twenty":-1459.102337,"median":-394.674774,"eighty":-26.925021,"marketCap":4931269830},{"date":"2025-02-14","current":-19.646244,"twenty":-1457.642359,"median":-390.041762,"eighty":-26.782239,"marketCap":4247537655},{"date":"2025-02-21","current":-19.437413,"twenty":-1455.695721,"median":-30.305187,"eighty":-26.72172,"marketCap":4202388031},{"date":"2025-02-28","current":-18.385222,"twenty":-1452.094441,"median":-29.520901,"eighty":-26.562732,"marketCap":3974903390},{"date":"2025-03-07","current":-18.486889,"twenty":-1446.059864,"median":-28.777108,"eighty":-26.339693,"marketCap":3996883783},{"date":"2025-03-14","current":-16.449855,"twenty":-1440.122619,"median":-28.454992,"eighty":-26.179328,"marketCap":3556475076},{"date":"2025-03-21","current":-17.921046,"twenty":-1437.981318,"median":-28.198548,"eighty":-25.317223,"marketCap":3874548031},{"date":"2025-03-28","current":-18.76981,"twenty":-1430.38943,"median":-27.986257,"eighty":-24.094834,"marketCap":4058051659},{"date":"2025-04-04","current":-16.296269,"twenty":-1422.116219,"median":-27.889753,"eighty":-20.198845,"marketCap":3523269657},{"date":"2025-04-11","current":-15.87621,"twenty":-1419.974918,"median":-27.820821,"eighty":-19.520945,"marketCap":3432452458},{"date":"2025-04-17","current":-15.802935,"twenty":-1417.346957,"median":-27.682957,"eighty":-19.180725,"marketCap":3416610370},{"date":"2025-04-25","current":-17.317281,"twenty":-1415.400319,"median":-27.425612,"eighty":-18.846182,"marketCap":3744013527},{"date":"2025-05-02","current":-17.960471,"twenty":-1411.604376,"median":-27.370467,"eighty":-18.532156,"marketCap":3883071858},{"date":"2025-05-09","current":-18.233962,"twenty":-1408.19776,"median":-27.329108,"eighty":-18.405555,"marketCap":4289685457},{"date":"2025-05-16","current":-21.240398,"twenty":-1401.871187,"median":-27.223413,"eighty":-18.515128,"marketCap":4996973579},{"date":"2025-05-23","current":-21.307828,"twenty":-1386.882076,"median":-27.071763,"eighty":-18.645114,"marketCap":5012836988},{"date":"2025-05-30","current":-20.970679,"twenty":-1384.546111,"median":-26.979854,"eighty":-18.713226,"marketCap":4933519947},{"date":"2025-06-06","current":-21.779837,"twenty":-1366.053052,"median":-26.837395,"eighty":-18.714534,"marketCap":5123880845},{"date":"2025-06-13","current":-21.083062,"twenty":-1357.293182,"median":-26.745487,"eighty":-18.76981,"marketCap":4959958960},{"date":"2025-06-20","current":-21.397734,"twenty":-630.517125,"median":-26.722672,"eighty":-18.799724,"marketCap":5033988198},{"date":"2025-06-27","current":-20.715944,"twenty":-446.043303,"median":-26.635196,"eighty":-18.835877,"marketCap":4873591516},{"date":"2025-07-03","current":-19.974216,"twenty":-441.960461,"median":-26.551186,"eighty":-18.852455,"marketCap":4699094026},{"date":"2025-07-11","current":-19.329886,"twenty":-438.862005,"median":-26.400131,"eighty":-18.891318,"marketCap":4547510347},{"date":"2025-07-18","current":-18.603142,"twenty":-435.145985,"median":-26.322706,"eighty":-18.792246,"marketCap":4376538059},{"date":"2025-07-25","current":-18.767971,"twenty":-431.217662,"median":-26.184843,"eighty":-18.769074,"marketCap":4415315279},{"date":"2025-08-01","current":-17.868906,"twenty":-429.132806,"median":-25.973452,"eighty":-18.719624,"marketCap":4203803170},{"date":"2025-08-08","current":-16.647677,"twenty":-428.119335,"median":-25.013004,"eighty":-18.618108,"marketCap":3916499222},{"date":"2025-08-15","current":-15.000942,"twenty":-427.308558,"median":-24.227183,"eighty":-18.552195,"marketCap":3687831610},{"date":"2025-08-22","current":-15.038842,"twenty":-426.26613,"median":-22.921489,"eighty":-18.339199,"marketCap":3697149022},{"date":"2025-08-29","current":-15.031262,"twenty":-424.84727,"median":-21.776091,"eighty":-18.209869,"marketCap":3695285539},{"date":"2025-09-05","current":-14.902401,"twenty":-422.588676,"median":-21.667454,"eighty":-17.977035,"marketCap":3663606339},{"date":"2025-09-12","current":-14.629519,"twenty":-419.519305,"median":-21.457672,"eighty":-17.846429,"marketCap":3596520974},{"date":"2025-09-19","current":-14.72806,"twenty":-417.405493,"median":-21.307828,"eighty":-17.519829,"marketCap":3620746244},{"date":"2025-09-26","current":-14.77354,"twenty":-413.351607,"median":-21.281605,"eighty":-17.355901,"marketCap":3631927139},{"date":"2025-10-03","current":-14.030694,"twenty":-406.749563,"median":-21.240398,"eighty":-17.207371,"marketCap":3449305866},{"date":"2025-10-10","current":-14.117865,"twenty":-400.610822,"median":-21.169222,"eighty":-16.756085,"marketCap":3470735914},{"date":"2025-10-17","current":-12.620803,"twenty":-398.265359,"median":-21.090554,"eighty":-16.357703,"marketCap":3102698146},{"date":"2025-10-24","current":-13.666851,"twenty":-397.193975,"median":-21.023124,"eighty":-16.016618,"marketCap":3359858713},{"date":"2025-10-30","current":-13.772972,"twenty":-395.977809,"median":-20.993156,"eighty":-15.87621,"marketCap":3385947466}],"updateTime":1761979145728},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OS\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2580410252","title":"CounterPoint：AI手机不到2年全球累计出货量破5亿台","url":"https://stock-news.laohu8.com/highlight/detail?id=2580410252","media":"IT之家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580410252?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 07:20","pubTimestamp":1761952859,"startTime":"0","endTime":"0","summary":"IT之家 11 月 1 日消息，市场调查机构 CounterPoint Research 昨日 发布博文，报告称 2025 年第 3 季度，全球生成式 AI 手机在不到 2 年时间内，累计出货量已突破 5 亿部。该机构指出生成式 AI 手机于 2023 年年末首次亮相，截至 2025 年第 3 季度，其全球累计出货量已正式突破 5 亿部。消费者对生成式 AI 手机的认知度已达到新高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8nux0EMcAps","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["OS","BK4551","BK4585","BK4543","BK4528","AI","BK4587","BK4097","BK4023","BK4588"],"gpt_icon":0},{"id":"2580410544","title":"Onestream, Inc.盘中异动 临近收盘快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580410544","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580410544?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 03:31","pubTimestamp":1761939065,"startTime":"0","endTime":"0","summary":"北京时间2025年11月01日03时31分，Onestream, Inc.股票出现异动，股价急速拉升5.02%。Onestream, Inc.股票所在的软件服务行业中，整体跌幅为0.15%。Onestream, Inc.公司简介：OneStream Inc 是一个支持人工智能且可扩展的软件平台，能够在单一平台上统一核心财务功能以及更广泛的运营数据和流程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110103310594e7e1c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110103310594e7e1c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4097"],"gpt_icon":0},{"id":"2578509299","title":"Os Therapies Incorporated盘中异动 股价大涨6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578509299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578509299?lang=zh_cn&edition=fundamental","pubTime":"2025-10-25 03:57","pubTimestamp":1761335849,"startTime":"0","endTime":"0","summary":"北京时间2025年10月25日03时57分，Os Therapies Incorporated股票出现波动，股价快速上涨6.08%。截至发稿，该股报1.92美元/股，成交量27.5883万股，换手率0.82%，振幅4.97%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.08%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025035729a6cc92de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025035729a6cc92de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OSTX","BK4139","BK4097","OS"],"gpt_icon":0},{"id":"2576547890","title":"三大运营商eSIM商用启幕 哪些产业链企业受益？|eSIM重返系列观察①","url":"https://stock-news.laohu8.com/highlight/detail?id=2576547890","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576547890?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 23:28","pubTimestamp":1760714902,"startTime":"0","endTime":"0","summary":"10月13日，中国电信、中国移动、中国联通三大运营商正式官宣，已获得工业和信息化部颁发的eSIM手机运营服务商用试验批复许可，并全面上线eSIM手机业务。这标志着我国eSIM技术正式突破智能穿戴、物联网设备领域，迈入手机端商用新阶段，也为eSIM产业链带来新的增长契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510173537587662.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510173537587662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4097","OS"],"gpt_icon":0},{"id":"2576886096","title":"Os Therapies Incorporated盘中异动 快速下跌5.14%报1.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576886096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576886096?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 22:13","pubTimestamp":1760710391,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日22时13分，Os Therapies Incorporated股票出现波动，股价急速下挫5.14%。截至发稿，该股报1.76美元/股，成交量33.3201万股，换手率0.99%，振幅6.91%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.05%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017221312a4654783&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017221312a4654783&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4539","RANI","BK4139","OS","ARTV","BK4097","OSTX"],"gpt_icon":0},{"id":"2575760877","title":"告别繁琐！让AI当你的“生活管家”，是种怎样的体验？","url":"https://stock-news.laohu8.com/highlight/detail?id=2575760877","media":"智东西","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575760877?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 10:40","pubTimestamp":1760582407,"startTime":"0","endTime":"0","summary":"当下AI圈的热议焦点，往往萦绕于“万亿参数”、“算力突破”等宏大叙事。AI在这里扮演的不是搜索引擎，而是一步到位的服务执行者。在大会现场，AI的演进正经历一场从“控制”到“关怀”的本质蜕变。在陪伴与成长中，AI的角色进化为 “有成长的伙伴”。这也是中国移动董事长杨杰在“AI+”行动中，所提到的“AI+民生保障”的表现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8nUginmB9UB","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["AI","LU0871576103.HKD","BK4097","00941","LU0531971595.HKD","LU1497733557.USD","LU0067412154.USD","80883","LU0039217434.USD","LU1152091754.HKD","LU1226287792.SGD","LU2148510915.USD","HK0000500386.USD","LU1522347837.USD","LU1951186391.HKD","SG9999002463.SGD","LU1497733631.SGD","BK4543","LU0164865239.USD","LU1226288170.HKD","BK4528","BK4551","LU1008478684.HKD","BK1521","LU0880133367.SGD","BK4023","LU1634259391.SGD","LU0164880469.USD","LU1226287529.USD","LU1064130708.USD","HK0000252160.HKD","LU1226287875.USD","BK1610","OS","BK1589","LU1152091168.USD","BK1152","LU1226288253.USD","BK4587","LU1481107354.HKD","LU0149721374.USD","BK1506","BK4585","LU1497734951.SGD","LU1634259557.SGD","BK1536","BK4588","HK0000252152.HKD","LU1064131003.USD"],"gpt_icon":0},{"id":"2575404305","title":"科伦博泰旗下抗癌药新适应症获批，上半年该药贡献超9成药品销售收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2575404305","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575404305?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 21:12","pubTimestamp":1760361157,"startTime":"0","endTime":"0","summary":"红星资本局10月13日消息，科伦博泰（06990.HK）昨日晚间公告称，旗下药物芦康沙妥珠单抗（佳泰莱?）获得国家药监局批准，用于治疗经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510133532577979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","06990","BK4097","LU0196878994.USD","BK1161","BC","BK4190"],"gpt_icon":0},{"id":"2574243025","title":"防晒剂龙头创始人逝世","url":"https://stock-news.laohu8.com/highlight/detail?id=2574243025","media":"青眼","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574243025?lang=zh_cn&edition=fundamental","pubTime":"2025-10-11 17:57","pubTimestamp":1760176620,"startTime":"0","endTime":"0","summary":"截至该公告披露日，周久京直接持有科思股份2310万股，占公司股份总额的4.86%，为公司2名实际控制人之一。据悉，周久京逝世前未在科思股份担任任何具体职务。▍截自科思股份公告业绩承压今年上半年营收同比下滑近49%作为“美妆防晒第一股”，科思股份的崛起，却是从合成香料开始。例如，在今年5月的投资者关系文件中，科思股份解释称，2024年业绩下滑的原因，一部分源于防晒剂市场竞争加剧的背景之下，其选择了下调产品价格。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-11/doc-inftpmam4915032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0731783048.USD","OMC","LU0731783394.SGD","BK4097","LU0321505439.SGD","LU1599440770.SGD","EHT","AVB","LU0772969993.USD","BK4215","LU0321505868.SGD","LU1481011671.HKD","OS","LU0742537680.HKD","LU1509826696.USD","BK4009","LU1481011911.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2574154301","title":"德达博妥单抗三阴乳腺癌一线治疗新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2574154301","media":"医药地理","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574154301?lang=zh_cn&edition=fundamental","pubTime":"2025-10-09 17:03","pubTimestamp":1760000637,"startTime":"0","endTime":"0","summary":"德达博妥单抗是一款靶向TROP2的DXd抗体偶联药物，由第一三共研发，并由阿斯利康与第一三共共同开发与商业化。目前，德达博妥单抗已在全球35个以上国家和地区获批，用于治疗经既往内分泌治疗及化疗后、不可切除或转移性HR阳性、HER2阴性乳腺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251009171758a6b1b702&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU2236285917.USD","BK4097","BK4588","LU0320765992.SGD","LU2456880835.USD","BK4211","BK4585","LU2417539215.USD","BK4195","BK4007","AZN","LU0109394709.USD","LU2462157665.USD","OS","PFS","LU1829250122.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2573939896","title":"第一三共公布TROPION-Breast02 Ⅲ期研究积极的主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2573939896","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573939896?lang=zh_cn&edition=fundamental","pubTime":"2025-10-07 12:19","pubTimestamp":1759810770,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ADC","OS","BK4231","BK4195","BK4211","PFS","BK4097","BK4080"],"gpt_icon":0},{"id":"2572950304","title":"破局肺癌长生存难题 百泽安全线刷新OS获益纪录","url":"https://stock-news.laohu8.com/highlight/detail?id=2572950304","media":"E药经理人","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572950304?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 17:35","pubTimestamp":1759224951,"startTime":"0","endTime":"0","summary":"在中国发病率、死亡率居首的肺癌领域，患者追求长期生存的目标，正变得不再遥不可及。尤其在发病率居全球恶性肿瘤首位的肺癌领域，OS获益的重要性显得更为突出。02百泽安成肺癌“长生存”破局者在本届WCLC大会上，除了围术期RATIONALE-315研究，替雷利珠单抗还公布了其用于二线/三线局部晚期或转移性NSCLC患者治疗的RATIONALE-303研究最新OS随访数据，5年生存率达到20.1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930200632a6a867a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930200632a6a867a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0053671581.USD","ONC","BK4161","LU0054578231.USD","ITT","BK4526","BK4097","OS","BK4139","BK4585"],"gpt_icon":0},{"id":"2568239777","title":"Os Therapies Incorporated盘中异动 早盘急速跳水6.67%报2.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568239777","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568239777?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 21:55","pubTimestamp":1758203735,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日21时55分，Os Therapies Incorporated股票出现波动，股价急速下挫6.67%。截至发稿，该股报2.05美元/股，成交量7.2274万股，换手率0.23%，振幅3.64%。Os Therapies Incorporated股票所在的生物技术行业中，整体涨幅为0.68%。Os Therapies Incorporated公司简介：OS Therapies Inc 是一家临床阶段的生物制药公司，专注于骨肉瘤和其他实体肿瘤治疗的鉴定、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918215535a4cddfc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918215535a4cddfc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OS","BK4097","OSTX"],"gpt_icon":0},{"id":"2566665256","title":"医保基金监管细则公开征求意见发布；第一三共新生产大楼开工","url":"https://stock-news.laohu8.com/highlight/detail?id=2566665256","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566665256?lang=zh_cn&edition=fundamental","pubTime":"2025-09-09 10:05","pubTimestamp":1757383554,"startTime":"0","endTime":"0","summary":"政策动向《中药生产监督管理专门规定》发布9月8日，国家药监局公布《中药生产监督管理专门规定》（以下简称《规定》），自2026年3月1日起施行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509093508530127.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509093508530127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","02257","BK4097","ADC","BK4231","BK4080","BK1161"],"gpt_icon":0},{"id":"2565680637","title":"打败“药王”后康方出海数据屡发股价屡跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2565680637","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565680637?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 22:05","pubTimestamp":1757340300,"startTime":"0","endTime":"0","summary":"康方生物的依沃西单抗作为全球首创PD-1/VEGF双靶点抗肿瘤药，曾在国内试验中击败“药王”K药。9月7日，康方生物发布依沃西单抗海外临床试验最新数据，显示生存获益较此前5月分析结果有明显改善趋势，但9月8日，康方生物股价下跌7.89%，其海外合作伙伴Summit开盘跌17.5%。FDA前临床高级审评员认为，此次发布的数据仍不能说明已达到总生存期（OS）的显著获益，而OS数据是肿瘤药物能否获批上市的最重要指标。9月7日的数据是对5月底全球多中心三期试验结果的更新，5月底数据显示OS数据虽呈改善趋势，但未达到试验标准中的统计学显著性获益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908222513a4bb8f74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250908222513a4bb8f74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OS","BK4097","09926"],"gpt_icon":0},{"id":"2566630016","title":"泰瑞沙联合化疗方案显示出近四年的中位总生存期（OS），这是EGFR敏感突变阳性晚期非小细胞肺癌全球III期临床研究中报道的最长*生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2566630016","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566630016?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 21:10","pubTimestamp":1757337000,"startTime":"0","endTime":"0","summary":"阿斯利康正继续探索奥希替尼用于治疗不同疾病分期的EGFR突变非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4767740_ZH67740_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["III","LU0320765992.SGD","OS","LU2417539215.USD","BK4568","LU0889565916.HKD","LU1829250122.USD","BK4134","LU2456880835.USD","AZN","BK4007","BK4097","LU2236285917.USD","BK4585","LU2462157665.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2565850646","title":"百济神州今日宣布RATIONALE-315研究的最终分析结果和RATIONALE-303研究的长期随访数据显示百泽安（替","url":"https://stock-news.laohu8.com/highlight/detail?id=2565850646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565850646?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 19:38","pubTimestamp":1757331495,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU1719994722.HKD","LU0307460666.USD","BK4097","BK1588","06160","LU0588546209.SGD","LU1251922891.USD","688235","BK1583","OS","ONC","BK4139","LU1969619763.USD","BK1500","BK0239","LU1303224171.USD","BK4585","LU1770034418.SGD","LU2328871848.SGD","BK4526"],"gpt_icon":0},{"id":"2565794405","title":"中信里昂：维持康方生物(09926.HK)目标价177港元 评级“跑赢大市“","url":"https://stock-news.laohu8.com/highlight/detail?id=2565794405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565794405?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 10:00","pubTimestamp":1757296826,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU2476274720.SGD","LU0348827113.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0348783233.USD","BK4097","09926","LU2488822045.USD","BK4539","LU0634319403.HKD","LU0348784397.USD","LU0348766576.USD","LU0417516902.SGD","LU0417516738.SGD","III","LENZ","LU1794554557.SGD","LU0561508036.HKD","OS","BK1574","LU1720050803.USD","IE00B543WZ88.USD","LU2476274308.USD","LU0540923850.HKD","LU0348767384.USD","LU0348825331.USD","LU2778985437.USD","BK4139","IE00BPRC5H50.USD","BK4134","BK4007"],"gpt_icon":0},{"id":"2565198595","title":"1400亿广东明星药企，筹资35亿出征全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2565198595","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565198595?lang=zh_cn&edition=fundamental","pubTime":"2025-09-06 17:31","pubTimestamp":1757151073,"startTime":"0","endTime":"0","summary":"一支广东中山的创新药团队，再次募得巨资。9月4日，康方生物公告，已完成新一轮配售，发行新股2355万股，募资近35亿港元。董事会主席、总裁兼CEO夏瑜，及其同事李百勇，也同期出让部分股权。这两年，康方已有三轮募资，筹集金额超过65亿港元。夏瑜领导的这家明星药企，正面临商业爬坡期与临床高投入期的双重压力，其已有7款自研产品上市，加之庞大的后期管线在快速推进，需要持续的资金支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509063506758557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509063506758557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999014542.SGD","LU1974910355.USD","BK4007","LU1794554557.SGD","LU1941712264.USD","MRK","SG9999015358.SGD","LU1917777945.USD","IE00BPRC5H50.USD","LU1989772840.SGD","LU2023250504.SGD","LU0058720904.USD","LU0211331839.USD","LU1037948897.HKD","09926","OS","LU0320765646.SGD","LU0070302665.USD","LU1037948541.HKD","LU0348767384.USD","LU1989771016.USD","LU0417516571.SGD","LU2112291526.USD","SG9999014567.USD","LU0965509010.AUD","LU1035773651.USD","SG9999014559.SGD","BK4550","BK4516","SG9999014575.USD","IE00BFTCPJ56.SGD","LU0348825331.USD","LU2476274720.SGD","LU0965509283.SGD","LU1934455277.USD","LU2488822045.USD","LU1066051811.HKD","LU2778985437.USD","LU1057294990.SGD","LU0234572021.USD","LU1934455863.HKD","SG9999002224.SGD","LU0348766576.USD","LU0540923850.HKD","IE0002141913.USD","LU0122379950.USD","LU1069347547.HKD","LU1983299246.USD","LU2361044949.HKD","LU0965508806.USD"],"gpt_icon":0},{"id":"2562701704","title":"“大牛股”康方生物，核心产品大卖亏损却扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2562701704","media":"时代财经APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562701704?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 12:12","pubTimestamp":1756354374,"startTime":"0","endTime":"0","summary":"财报数据显示，今年上半年，康方生物总收入为14.12亿元，同比增长37.75%。在商业授权收入方面，康方生物在今年上半年已收到990万元。不过，截至今年上半年，康方生物仍处于亏损状态，且亏损金额进一步扩大，为5.88亿元，这一数字在去年同期为亏损2.49亿元。投资者更为关注的是，康方生物核心产品的研发和商业化销售情况，尤其是依沃西在全球市场头对头试验进展。上述相关负责人表示，今年上半年，康方生物在中国市场医院覆盖进一步深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828125215a4a424fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014542.SGD","LU1974910355.USD","BK4008","LU1929549753.HKD","SG9999015341.SGD","BK4007","LU1941712264.USD","MRK","ALK","LU2023250504.SGD","LU0058720904.USD","LU0211331839.USD","LU1585245621.USD","OS","LU0070302665.USD","IE00BJT1NW94.SGD","LU1037948541.HKD","BK4534","SG9999001176.SGD","LU1093756325.SGD","LU0106261372.USD","LU1989772923.USD","LU1061106388.HKD","LU0208291251.USD","IE000M9KFDE8.USD","IE00BN8TJ469.HKD","LU1116320737.USD","BK4107","LU2487616109.SGD","LU0203347892.USD","LU0965509010.AUD","LU1035773651.USD","LU1023059063.AUD","SG9999001440.SGD","BK4585","IE00BSNM7G36.USD","BK4516","LU2023250843.SGD","SG9999014575.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1934455277.USD","LU1057294990.SGD","LU1066051225.USD","LU1934455863.HKD","LU2468319806.SGD","SG9999013999.USD","LU2106854487.HKD","L","LU2324357040.USD"],"gpt_icon":0},{"id":"2562709883","title":"康方生物Key data readouts for AK112 to validate","url":"https://stock-news.laohu8.com/highlight/detail?id=2562709883","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562709883?lang=zh_cn&edition=fundamental","pubTime":"2025-08-28 11:21","pubTimestamp":1756351315,"startTime":"0","endTime":"0","summary":"AK104和AK112两款药物分别因纳入国家医保目录，在二线及以上的宫颈癌和EGFR突变非小细胞肺癌治疗中推动了销售增长。预计到2026年，随着更多适应症进入NRDL，如一线胃癌、一线宫颈癌和PD-L1阳性非小细胞肺癌等，将进一步加速产品销售。同时，公司计划启动一项针对IO耐药二线肝细胞癌的全球II期注册试验，并探索AK104与AK112联合用药的可能性。此外，Akeso还正在开发HER3ADC和Trop2/Nectin4ADC等早期项目，进一步丰富其研发管线。与此同时，AK104的国际合作潜力也被看好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828114047a4a40388&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4211","PFS","OS","BK4195","BK4097"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}